Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer
Citations Over TimeTop 10% of 2013 papers
Abstract
Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed. It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development. Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients. Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.
Related Papers
- → Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer(2011)547 cited
- → Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer(2013)57 cited
- → Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect(2023)28 cited
- → Cabozantinib for progressive metastatic medullary thyroid cancer: a review(2014)16 cited
- Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer(2013)